This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
Ixekizumab reduces erosion and increases backfill in the sacroiliac joints of patients with radiographic axial spondyloarthritis by week 16, with continued improvement through week 52.
Medscape Medical News